Global Ion Channel Modulators Industry

News provided by

Sep 07, 2015, 03:32 ET

LONDON, Sept. 7, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Ion Channel Modulators in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2018. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 47 companies including many key and niche players such as -

AstraZeneca

Bayer HealthCare

CalciMedica, Inc.

Convergence Pharmaceuticals Limited

Evotec AG

Download the full report: https://www.reportbuyer.com/product/1171462/

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Ion Channel Modulators - A Receding Market II-1

Current and Future Analysis II-1

Impending Patent Expiries of Select Ion Channel Modulators II-2

Currently Available Ion Channel Modulating Drugs in the Market II-2

Select Ion Channel Modulator Drugs by Mode of Action II-3

Competitive Scenario II-6

Table 1: Global Ion Channel Modulators Market by Top Ten

Drugs (2013): Percentage Share Breakdown of Revenues

(includes corresponding Graph/Chart) II-6

2. ION CHANNEL MODULATORS BY THERAPEUTIC INDICATION II-7Cardiovascular Diseases/ Hypertension II-7Select Major Anti-Hypertensive Drugs Targeting Ion Channels:2014 II-7Table 2: Global Annual Medical Cost of CVD in US$ Billion(2010-2030) (includes corresponding Graph/Chart) II-8

Table 3: Fatalities by Heart Conditions - Estimated

Percentage Breakdown for Cardiovascular Disease, Ischemic

Heart Disease, Stroke, and Others (includes corresponding

Graph/Chart) II-8

Table 4: Fatalities in High Income Countries by HealthDisorder (2015 & 2030): Projected Percentage Breakdown ofNumber of Deaths for CVD, Cancer, Injury, and Others(includes corresponding Graph/Chart) II-9

Table 5: Fatalities in Mid Income Countries by Health

Disorder (2015 & 2030): Projected Percentage Breakdown of

Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria;

Malnutrition; and Others (includes corresponding Graph/Chart) II-10

Table 6: Fatalities in Low Income Countries by HealthDisorder (2015 & 2030): Projected Percentage Breakdown ofNumber of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria;Malnutrition; and Others (includes corresponding Graph/Chart) II-11Ion Channel Modulation in Arrhythmia Treatment II-11Select Anti-Arrhythmic Drugs Targeting Ion Channels: 2014 II-11Ion Channel Modulation in Convulsions II-12Select Anti-Convulsant Drugs Targeting Ion Channels: 2014 II-12Ion Channel Modulation in Pain Management II-13Pain Management/Analgesic Drugs Targeting Ion Channels: 2014 II-14Ion Channel Modulation in Oncology II-14Ion Channel Modulation of Antidiabetic Agents II-14Ion Channel Modulation of Antiemetics II-15Ion Channel Modulators Find Extensive Use in NeglectedTropical Diseases II-15Ion Channel Modulation in Other Therapeutic Areas II-15Select Ion Channel Modulators for Other TherapeuticIndications: 2014 II-16

3. MARKET DYNAMICS II-17

Aging Population: Sustaining the Market II-17

Table 7: Global Population Worldwide: Percentage Share

Breakdown by Age Group for the year 2025 (includes

corresponding Graph/Chart) II-17

Table 8: Global Population of People Aged 65+ Years (InMillion) for the Years 2012, 2020 & 2050 (includescorresponding Graph/Chart) II-17Ion Channel Screening Aided by APC II-18Increased Interest Witnessed in Outsourcing of Ion ChannelServices II-18Limitations and Challenges II-18Ion Channels - Difficult Drug Targets II-18The Threat Posed by the Influx of Generic Drugs II-19

4. PRODUCT OVERVIEW II-20

Ion Channel Modulators: An Introduction II-20

Biological Significance of Ion Channels II-20

Ion Channel Modulators as an Option for Treating Diseases II-20

Types of Ion Channels II-21

Voltage-Gated Ion Channels II-21

Extracellular Ligand-gated Ion Channels II-22

Intracellular Ligand-gated Ion Channels II-24

5. RECENT INDUSTRY ACTIVITY II-26Pfizer Wins Court Ruling to Block Generic Versions of LyricaUpto 2018 II-26Forest Labs Discontinues Namenda 5/10 mg Tablets, LaunchesNamenda XR II-26Forest Files Lawsuit against Namenda Generic Manufacturers II-26Cytocentrics Bioscience Selects Drug Safety Testing Center asits Distributor in Japanese Market II-26Zalicus Licenses Its Entire Sodium Channel Modulator Programto AnaBios Corporation II-26EPIRUS Merges with Zalicus II-26XENTION Collaborates with SERVIER for Kv1.5 Modulator Project II-27Aurora Biomed Inks Agreement with Specs and Alion Pharmaceuticals II-27Hydra and Zalicus Enter into Partnership II-27Hydra Biosciences and Cubist Pharmaceuticals to Commence Phase1 Clinical Trial for TRPA1 Antagonist CB-625 II-27Vertex Pharmaceuticals Receives USFDA Approval for KALYDECO™ II-27

6. FOCUS ON SELECT GLOBAL PLAYERS II-28

AstraZeneca (UK) II-28

Bayer HealthCare (Germany) II-28

CalciMedica, Inc. (US) II-29

Convergence Pharmaceuticals Limited (UK) II-29

Evotec AG (Germany) II-29

Forest Laboratories, LLC (US) II-30

GlaxoSmithKline Plc. (UK) II-30

Johnson & Johnson (US) II-31

Lundbeck (Denmark) II-31

Novartis AG (Switzerland) II-32

Parion Sciences, Inc. (US) II-32

Pfizer, Inc. (US) II-32

Neusentis, Inc. (US) II-33

Sanofi S.A. (France) II-33

Targacept, Inc. (US) II-34

Xention Limited (UK) II-35

7. GLOBAL MARKET PERSPECTIVE II-36Table 9: World Recent Past, Current and Future Analysis forIon Channel Modulators by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), Latin America,and Rest of World Markets Independently Analyzed with AnnualSales in US$ Million for Years 2014 through 2018 (includescorresponding Graph/Chart) II-36

Table 10: World Historic Review for Ion Channel Modulators by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America, and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2013 (includes corresponding Graph/Chart) II-37

Table 11: World 12-Year Perspective for Ion Channel Modulatorsby Geographic Region - Percentage Breakdown of Dollar Salesfor US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Latin America, and Rest of World Markets for Years 2007, 2015 &2018 (includes corresponding Graph/Chart) II-38III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Overview III-1

Strategic Corporate Developments III-1

Select Key Players III-2

B.Market Analytics III-6

Table 12: The US Recent Past, Current and Future Analysis

for Ion Channel Modulators with Annual Sales in US$ Million

for Years 2014 through 2018 (includes corresponding

Graph/Chart) III-6

Table 13: The US Historic Review for Ion Channel Modulatorswith Annual Sales in US$ Million for Years 2007 through 2013(includes corresponding Graph/Chart) III-7

2. CANADA III-8

A.Market Analysis III-8

Strategic Corporate Development III-8

B.Market Analytics III-8

Table 14: Canadian Recent Past, Current and Future Analysis

for Ion Channel Modulators with Annual Sales in US$ Million

for Years 2014 through 2018 (includes corresponding

Graph/Chart) III-8

Table 15: Canadian Historic Review for Ion ChannelModulators with Annual Sales in US$ Million for Years 2007through 2013 (includes corresponding Graph/Chart) III-9

3. JAPAN III-10

A.Market Analysis III-10

Strategic Corporate Development III-10

B.Market Analytics III-11

Table 16: Japanese Recent Past, Current and Future Analysis

for Ion Channel Modulators with Annual Sales in US$ Million

for Years 2014 through 2018 (includes corresponding

Graph/Chart) III-11

Table 17: Japanese Historic Review for Ion ChannelModulators with Annual Sales in US$ Million for Years 2007through 2013 (includes corresponding Graph/Chart) III-12

4. EUROPE III-13

A.Market Analysis III-13

Overview III-13

B.Market Analytics III-14

Table 18: European Recent Past, Current and Future Analysis

for Ion Channel Modulators by Geographic Region - France,

Germany, Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2014 through 2018 (includes corresponding Graph/Chart) III-14

Table 19: European Historic Review for Ion ChannelModulators by Geographic Region - France, Germany, Italy,UK, Spain, Russia and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2007through 2013 (includes corresponding Graph/Chart) III-15

Table 20: European 12-Year Perspective for Ion Channel

Modulators by Geographic Region - Percentage Breakdown of

Dollar Sales for France, Germany, Italy, UK, Spain, Russia

and Rest of Europe Markets for Years 2007, 2015 & 2018

(includes corresponding Graph/Chart) III-16

4a. FRANCE III-17A.Market Analysis III-17Sanofi S.A. - A Key Player III-17B.Market Analytics III-18Table 21: French Recent Past, Current and Future Analysisfor Ion Channel Modulators with Annual Sales in US$ Millionfor Years 2014 through 2018 (includes correspondingGraph/Chart) III-18

Table 22: French Historic Review for Ion Channel Modulators